A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL

Elizabeth Price, Andrew S. Artz, Huiman Barnhart, Shelly Sapp, Gordon Chelune, William B. Ershler, Jeremy D Walston, Victor R. Gordeuk, Nathan A. Berger, David Reuben, Josef Prchal, Sunil V. Rao, Cindy N. Roy, Mark A. Supiano, Stanley L. Schrier, Harvey Jay Cohen

Research output: Contribution to journalArticle

Abstract

Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

Original languageEnglish (US)
Pages (from-to)221-230
Number of pages10
JournalBlood Cells, Molecules, and Diseases
Volume53
Issue number4
DOIs
StatePublished - Dec 1 2014

Fingerprint

saccharated ferric oxide
Ferritins
Anemia
Serum
Control Groups
Hemoglobins
Outpatients
Iron
Quality of Life
Outcome Assessment (Health Care)
Morbidity
Mortality

Keywords

  • 6-Minute walk test
  • Hemoglobin
  • Intravenous iron
  • Unexplained anemia

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology
  • Cell Biology

Cite this

A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL. / Price, Elizabeth; Artz, Andrew S.; Barnhart, Huiman; Sapp, Shelly; Chelune, Gordon; Ershler, William B.; Walston, Jeremy D; Gordeuk, Victor R.; Berger, Nathan A.; Reuben, David; Prchal, Josef; Rao, Sunil V.; Roy, Cindy N.; Supiano, Mark A.; Schrier, Stanley L.; Cohen, Harvey Jay.

In: Blood Cells, Molecules, and Diseases, Vol. 53, No. 4, 01.12.2014, p. 221-230.

Research output: Contribution to journalArticle

Price, E, Artz, AS, Barnhart, H, Sapp, S, Chelune, G, Ershler, WB, Walston, JD, Gordeuk, VR, Berger, NA, Reuben, D, Prchal, J, Rao, SV, Roy, CN, Supiano, MA, Schrier, SL & Cohen, HJ 2014, 'A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL', Blood Cells, Molecules, and Diseases, vol. 53, no. 4, pp. 221-230. https://doi.org/10.1016/j.bcmd.2014.06.003
Price, Elizabeth ; Artz, Andrew S. ; Barnhart, Huiman ; Sapp, Shelly ; Chelune, Gordon ; Ershler, William B. ; Walston, Jeremy D ; Gordeuk, Victor R. ; Berger, Nathan A. ; Reuben, David ; Prchal, Josef ; Rao, Sunil V. ; Roy, Cindy N. ; Supiano, Mark A. ; Schrier, Stanley L. ; Cohen, Harvey Jay. / A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL. In: Blood Cells, Molecules, and Diseases. 2014 ; Vol. 53, No. 4. pp. 221-230.
@article{f2360f2f1cba45e28b7ae83d155300ed,
title = "A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL",
abstract = "Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.",
keywords = "6-Minute walk test, Hemoglobin, Intravenous iron, Unexplained anemia",
author = "Elizabeth Price and Artz, {Andrew S.} and Huiman Barnhart and Shelly Sapp and Gordon Chelune and Ershler, {William B.} and Walston, {Jeremy D} and Gordeuk, {Victor R.} and Berger, {Nathan A.} and David Reuben and Josef Prchal and Rao, {Sunil V.} and Roy, {Cindy N.} and Supiano, {Mark A.} and Schrier, {Stanley L.} and Cohen, {Harvey Jay}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.bcmd.2014.06.003",
language = "English (US)",
volume = "53",
pages = "221--230",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200ng/mL

AU - Price, Elizabeth

AU - Artz, Andrew S.

AU - Barnhart, Huiman

AU - Sapp, Shelly

AU - Chelune, Gordon

AU - Ershler, William B.

AU - Walston, Jeremy D

AU - Gordeuk, Victor R.

AU - Berger, Nathan A.

AU - Reuben, David

AU - Prchal, Josef

AU - Rao, Sunil V.

AU - Roy, Cindy N.

AU - Supiano, Mark A.

AU - Schrier, Stanley L.

AU - Cohen, Harvey Jay

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

AB - Anemia is common in older persons and is associated with substantial morbidity and mortality. One third of anemic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control trial in outpatients with UAE and serum ferritin levels between 20 and 200. ng/mL. Intravenous iron sucrose was given as a 200-mg weekly dose for 5. weeks either immediately after enrollment (immediate intervention group) or following a 12-week wait list period (wait list control group). The primary outcome measure was changed in 6-minute walk test (6MWT) distances from baseline to 12. weeks between the two groups. Hematologic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after 19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate intervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p = 0.443). The hemoglobin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ± 0.85 g/dL in the wait list control group (p = 0.026). Thus, a subgroup of adults with UAE may respond to intravenous iron. Enrollment of subjects into this type of study remains challenging.

KW - 6-Minute walk test

KW - Hemoglobin

KW - Intravenous iron

KW - Unexplained anemia

UR - http://www.scopus.com/inward/record.url?scp=84908087455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908087455&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2014.06.003

DO - 10.1016/j.bcmd.2014.06.003

M3 - Article

VL - 53

SP - 221

EP - 230

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 4

ER -